Here are the 10-K annual reports from Rapid Micro Biosystems, Inc. (RPID) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RPID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPID filings page.
Rapid Micro Biosystems filed its annual report describing a business focused on automating microbial quality control in pharmaceutical manufacturing through its Growth Direct platform. The system replaces manual plate handling and visual colony counting with robotic automation, optical imaging and vision algorithms, targeting faster, more accurate and data-secure testing.
The company reports a large addressable market, estimating approximately $5.0 billion for system sales and a further $5.0 billion for recurring consumables and services. As of December 31, 2025, it had incurred an accumulated deficit of $522.4 million, including a net loss of $47.1 million for 2025 versus $46.9 million for 2024.
Rapid Micro Biosystems highlights positive gross margins in 2025 after prior investments in manufacturing and service infrastructure, but warns it may continue to incur losses and may need additional capital. It emphasizes growth initiatives around biologics and cell and gene therapies, a new rapid sterility test, integration with Lonza’s MODA-EM module, and a global distribution and collaboration agreement with MilliporeSigma that includes minimum system purchase commitments and potential supply-chain cost savings.